Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEDN6526A
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DEDN6526A is a humanized antibody-drug conjugate (ADC) designed to target the endothelin B receptor (ETBR), which is often overexpressed in melanoma and other tumor cells. The drug consists of a monoclonal antibody that specifically binds to ETBR on tumor cells and is linked to the cytotoxic agent monomethyl auristatin E (MMAE). Upon binding to ETBR-expressing cells, DEDN6526A is internalized; proteolytic cleavage then releases MMAE inside the cell. MMAE binds tubulin and inhibits its polymerization, leading to G2/M phase cell cycle arrest and apoptosis of the cancer cell. DEDN6526A was developed primarily for metastatic or unresectable melanoma[1][2][3][4][5].
- Other names
- anti-ETBR/MMAE antibody-drug conjugate
02
Targets
EDNRB (Endothelin receptor type B)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on DEDN6526A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEDN6526A.